Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GNLX
GNLX logo

GNLX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Genelux Corp (GNLX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.650
1 Day change
-5.02%
52 Week Range
8.540
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Genelux Corp (GNLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock lacks strong positive catalysts, has weak financial performance, and shows a bearish trend in the short term. Additionally, there are no significant trading signals or influential trading activity to support a buy decision.

Technical Analysis

The MACD histogram is positive and expanding, suggesting a bullish momentum. However, the RSI is neutral at 63.765, and moving averages are converging, indicating no strong trend. Key resistance levels are at 2.838 and 2.977, while support levels are at 2.387 and 2.248. The stock has a 70% chance of declining in the next day, week, and month, with a projected -3.41% drop in the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
4

Positive Catalysts

  • NULL identified. No recent news or significant trading activity from insiders, hedge funds, or influential figures.

Neutral/Negative Catalysts

  • The stock is projected to decline in the short term based on historical patterns. Financial performance is weak, with negative net income and declining EPS. Analyst price target was recently lowered from $23 to $20.

Financial Performance

In Q4 2025, revenue remained flat at 8000 YoY. Net income improved slightly by 3.02% YoY but remains negative at -9,247,000. EPS declined by -7.69% YoY to -0.24. Gross margin is 100%, but overall financial performance is weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Benchmark maintains a Speculative Buy rating but lowered the price target from $23 to $20, reflecting a less optimistic outlook.

Wall Street analysts forecast GNLX stock price to rise
4 Analyst Rating
Wall Street analysts forecast GNLX stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.790
sliders
Low
16
Averages
22.5
High
31
Current: 2.790
sliders
Low
16
Averages
22.5
High
31
Benchmark
Speculative Buy
downgrade
$23 -> $20
AI Analysis
2026-03-20
Reason
Benchmark
Price Target
$23 -> $20
AI Analysis
2026-03-20
downgrade
Speculative Buy
Reason
Benchmark lowered the firm's price target on Genelux to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the firm's sum-of-the-parts analysis for the new share count and moving the peak year assumption to 2033.
H.C. Wainwright
H.C. Wainwright
maintain
$31
2026-01-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$31
2026-01-05
maintain
Reason
Genelux reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/refractory lung cancer patients, outperforming historical response rates, with notable tumor shrinkage and signals of a dose-response effect at higher dosing, H.C. Wainwright tells investors in a research note. Early durability signals, including progression free survival extending to 12.1 months in one case despite single-cycle dosing and no maintenance therapy, suggest potential activity in overcoming platinum resistance, with further data expected in 2026, the firm says. H.C. Wainwright has a Buy rating and $31 price target on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GNLX
Unlock Now

People Also Watch